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Neoadjuvant chemotherapy followed by
cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy for colorectal
cancer: a feasibility and safety study
M. Leimkühler1†, P. H. J. Hemmer1*†, A. K. L. Reyners2, D. J. A. de Groot2, R. J. van Ginkel1, L. B. Been1,
G. H. de Bock3 and B. L. van Leeuwen1*
Abstract
Background: Standard treatment for colorectal peritoneal carcinomatosis typically involves cytoreductive surgery,
hyperthermic intraperitoneal chemotherapy (HIPEC), and if possible, postoperative adjuvant chemotherapy.
However, a substantial percentage of patients never receive adjuvant chemotherapy because of postoperative
complications. Neoadjuvant chemotherapy could be beneficial in this setting, so we assessed its feasibility and
safety when used before cytoreductive surgery and HIPEC.
Methods: In this non-randomized, single-center, observational feasibility study, patients were scheduled to receive
six cycles of capecitabine and oxaliplatin before cytoreductive surgery and HIPEC. Computed tomography was
performed after the third and sixth chemotherapy cycles to evaluate tumor response, and patients underwent
cytoreductive surgery and HIPEC if there were no pulmonary and/or hepatic metastases. Postoperative complications,
graded according to the Clavien–Dindo classification, were compared with those of a historic control group that
received postoperative adjuvant chemotherapy.
Results: Of the 14 patients included in the study, 4 and 3 had to terminate neoadjuvant chemotherapy early because
of toxicity and tumor progression, respectively. Cytoreductive surgery and HIPEC were performed in eight patients, and
the timing and severity of complications were comparable to those of patients in the historic control group treated
without neoadjuvant chemotherapy.
Conclusion: Patients with peritoneal metastases due to colorectal carcinoma can be treated safely with neoadjuvant
chemotherapy before definitive therapy with cytoreductive surgery and HIPEC.
Trial registration number: NTR 3905, registered on 20th march, 2013, http://www.trialregister.nl/trialreg/admin/
rctview.asp?TC=3905
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Background
Peritoneal carcinomatosis is common in patients with
colorectal cancer, occurring in 5–10% of those presenting
with synchronous peritoneal metastases and 20–50% of
those presenting with metachronous peritoneal metastases
[1]. If left untreated, the median patient survival of this
group is 3–9 months [2]. Therefore, peritoneal carcinoma-
tosis has long been considered an incurable disease [3],
with palliative treatment extending median progression-
free survival to just 6–12 months [4–6]. However, recent
developments in systemic treatment have increased the
2-year survival of patients from approximately 0% in 2000
to 10–16% in 2014 [6–8].
In recent years, many institutions started treating pa-
tients with cytoreductive surgery (CRS) and hyperthermia
intraperitoneal chemotherapy (HIPEC). A 5-year survival
between 33 and 58% has been described in patients with
colorectal carcinoma undergoing CRS plus HIPEC [9–11].
Because of this survival benefit, CRS plus HIPEC is
considered the treatment of choice for patients with
low-volume, low-grade peritoneal disease without sys-
temic dissemination [3]. Since 2006, systemic adjuvant
chemotherapy has been the logical treatment for preventing
hematogenous and lymphogenous spread. However, the
high postoperative complication rate following CRS and
HIPEC, which has ranged from 23 to 66% [2, 7, 12–15], can
leave many patients ineligible for adjuvant therapy, and no
studies have shown evidence of survival benefit for this
approach in patients with peritoneal carcinomatosis.
Nevertheless, it has also been shown that neoadjuvant
chemotherapy confers survival benefits in other tumors
[16–19], and on this basis, we thought that it could be
used before CRS and HIPEC in patients with colorectal
cancer. In this way, it might even help to reduce tumor
load and lessen the extent of surgery. A possible disadvan-
tage, however, might be that neoadjuvant chemotherapy
could negatively affect the postoperative complication
rate. At the time of writing, we could identify no prospect-
ive data on the efficacy of neoadjuvant systemic treatment
for this indication.
We conducted this feasibility study as a prequel to a
larger prospective multicenter study of the efficacy of
neoadjuvant systemic treatment in patients with peritoneal
carcinomatosis due to colorectal cancer. The primary aim
was to determine whether neoadjuvant chemotherapy
influenced postoperative complication and mortality rates
after CRS and HIPEC.
Methods
We conducted a non-randomized, single-center, observa-
tional feasibility study from April 2013 to July 2015 at the
University Medical Center Groningen (UMCG), which is
a referral center for HIPEC, serving 1.6 million inhabi-
tants. A historical control cohort of patients treated with
standard CRS and HIPEC, but without neoadjuvant
chemotherapy, served as a reference population (20). The
study was conducted in accordance with the Declaration
of Helsinki and approved by the Medical Ethics Committee
of the UMCG and was registered in the Dutch trial registry
(NTR 3905).
Patients
Patients were recruited from the UMCG if they had
peritoneal carcinomatosis of colorectal origin diagnosed
by computed tomography (CT), diagnostic laparoscopy,
or laparotomy. All diagnoses were confirmed by patho-
logical examination. The following eligibility criteria were
applied: World Health Organization (WHO) performance
score of 0 or 1, adequate bone marrow function (platelets
> 100 × 109, neutrophils > 1.5 × 109), and adequate renal
function (creatinine clearance > 50 mL/min).
The main exclusion criterion in the experimental group
was prior treatment with adjuvant systemic chemotherapy
within 12 months of the study. Patients were also excluded
if they had a history of other malignancies (except basal cell
carcinoma) or advanced liver disease (bilirubin > 34 μmol/L
and/or an international normalized ratio > 1.7). Finally, we
excluded patients with liver and/or extra-abdominal
metastases or neurotoxicity above grade 1 according
to The Common Terminology Criteria for Adverse
Events (Version 4.0) [20]. All included patients of the
experimental group provided a written informed
consent.
The historic reference population consisted of patients
with peritoneal carcinomatosis of colorectal origin who
were treated at the UMCG between 2006 and 2015 [21].
This reference population included 88 patients who
received standard treatment, consisting of CRS and
HIPEC, followed by adjuvant chemotherapy. We only
included patients with a peritoneal cancer index (PCI)
less than 20, because only this group has been shown to
benefit from HIPEC. Dutch law does not require informed
consent to use anonymized patient data for treatment
evaluation.
Standard treatment
Standard treatment involves CRS plus HIPEC followed by
cytoreductive surgery [22]. During surgery, all macro-
scopic lesions were removed, before intraperitoneal mito-
mycin C was given at a dose of 35 mg/m2 over 90 min.
This chemotherapy was administered in three doses, with
half given at the start of perfusion, one-quarter after
30 min, and one-quarter after 60 min; thereafter, perfusion
continued for 30 min [23].
Experimental treatment
The experimental protocol involved giving neoadjuvant
chemotherapy before CRS and HIPEC. Patients enrolled
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to this protocol were scheduled to receive six cycles of
capecitabine (1000 mg/m2) and oxaliplatin (130 mg/m2)
(i.e., CAPOX) every 3 weeks. Oxaliplatin was given
intravenously on the first day of each cycle and capecita-
bine was taken orally for 14 days in 21-day cycles. Before
CRS and HIPEC were performed, patients were given a
4-week recovery period after the last cycle of chemotherapy.
If the patient had not recovered satisfactorily by this time,
recovery could be extended to a maximum of 10 weeks. To
be eligible for surgery, patients were not allowed to have
leucopenia or thrombocytopenia, and were required to have
a WHO performance score of 2 or less. The CRS plus
HIPEC procedure followed the protocol described under
standard treatment.
CT scans were performed to provide a baseline as-
sessment before systemic treatment, and tumor re-
sponse was re-evaluated after three and six treatment
cycles. These evaluations were done by a radiologist,
according to the Response Evaluation Criteria in Solid
Tumors (RECIST) criteria [24]. If tumor progression
was seen on the follow-up CT, without extra-abdominal
or liver metastases, patients went directly for CRS and
HIPEC. If the tumor was non-resectable or if
extra-abdominal or liver metastases were present, pal-
liative surgery and/or palliative systemic treatment were
offered.
Data collection
Data were recorded for the following variables: primary
diagnosis, age, length of hospital stay, PCI, blood loss
during surgery, duration of surgery, complications during
systemic chemotherapy, complications in the 30 days
following CRS and HIPEC, whether the full chemotherapy
cycle was completed, disease progression, and survival.
Surgical complications were reported according to the
Clavien–Dindo classification [25]. Complications were
given by system, as follows: cardiovascular complications
included arrhythmias and deep vein thrombosis; pulmon-
ary complications included pneumonia, atelectasis, pleural
effusion, and pulmonary embolism; gastrointestinal compli-
cations included gastroparesis, excessive pain, and gastric
retention; mental complications included delirium and
excessive fear; and neurological complications included
neuropathy and impaired nerve function.
Primary outcome
To assess the feasibility of neoadjuvant chemotherapy,
we evaluated the surgical details, the postoperative com-
plications, and the mortality rates. In the experimental
group, this was done by an independent data monitoring
committee that was not connected to the study. This
comprised an oncology surgeon, a medical oncologist,
and an independent statistician. For the historic cohort,
all complications were reviewed by the independent
team who performed the earlier study [21].
Secondary outcomes
Secondary outcomes were blood loss, length of surgery,
and body mass index at the time of diagnosis (as a surro-
gate marker of advanced disease status). For the control
group, blood loss was only analyzed from 2010 because it
was not recorded before that date.
Feasibility
Neoadjuvant chemotherapy was determined feasible if
postoperative complications rates, perioperative blood
loss, and length of surgery were comparable between the
experimental and the historical control group.
Analysis
Descriptive analyses of the treatments and outcomes
were performed for patients in the experimental group. To
assess differences between the experimental and control
groups, 95% confidence intervals around the outcomes in
the historical cohort were calculated, and we determined
whether the values for the experimental patients were
within these confidence limits.
Results
The baseline characteristics of the 14 patients in the
experimental group and the 88 patients in the control
group are summarized in Table 1. Overall, the experi-
mental group was slightly older than the control group
and had a slightly higher median body mass index. In
the experimental group, peritoneal carcinomatosis was
synchronous in 10 patients and metachronous in 4; in
the control group, it was synchronous in 66 and meta-
chronous in 22. Figure 1 illustrates the treatment of the
patients in the experimental group.
Neoadjuvant chemotherapy
An overview of the treatment and outcomes is provided for
the experimental group in Table 2. Among the 14 patients
in the experimental group, 4 required a dose reduction and
Table 1 Patient and disease characteristics
Experimental group
N = 14
Control group N = 88




Gender Female 42.9% Female 51.8%
Male 57.1% Male 48.2%
BMI (median) 26.4 (range 20.31–35.08) 23.7 (range 11.47–40.04)
Origin of peritoneal
carcinomatosis
Colorectal 14 Colorectal 110
BMI body mass index
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7 terminated neoadjuvant treatment early (disease progres-
sion in 3 patients and toxicity in 4 patients). Two of the
patients with disease progression had extra-abdominal dis-
ease identified after one and four cycles of chemotherapy,
respectively, and neither of these proceeded to CRS and
HIPEC. Finally, one patient had a PCI > 20 after two cycles
of chemotherapy (extensive intra-abdominal disease), one
patient had a PCI > 20 after three cycles of chemotherapy,
and one had a PCI > 20 after six cycles of chemotherapy,
with all three being ineligible for CRS and HIPEC.
Fig. 1 Flowchart of patients treatment
Table 2 Treatment and outcomes in the experimental group
Patient Cycles of chemotherapy Stopped Reason for stopping Extra-abdominal metastasis Laparotomy PCI HIPEC Current status
1 1 Yes Toxicity No Yes 15 Yes, CC-0 DOD
2 6 No – No Yes 26 No DOD
3 6 No – No Yes 7 Yes, CC-0 AWD
4 6 No – No Yes 19 Yes, CC-0 DOD
5 3 Yes Progression No Yes 35 No DOD
6 6 No – No Yes 9 Yes, CC-0 NED
7 6 No – No Yes 1 Yes, CC-0 NED
8 6 No – No Yes 4 Yes, CC-0 AWD
9 3 Yes Progression Yes No – No AWD
10 6 No – No Yes 15 Yes, CC-0 NED
11 2 Yes Toxicity No Yes 30 No DOD
12 6 Yes – No Yes 1 Yes, CC-0 NED
13 1 Yes Progression Yes No 17 No DOD
14 4 Yes Toxicity No Yes 18 No AWD
DOD death of disease, AWD alive with disease, NED no evidence of disease
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The CRS and HIPEC procedure
Ultimately, eight patients with a median PCI of 15.3
underwent CRS and HIPEC in the experimental group.
In the control group, 88 patients underwent CRS and
HIPEC before adjuvant chemotherapy. The details of these
are compared in Table 3. As shown, median blood loss
was broadly comparable between the two groups, but the
lengths of surgery and hospital stay were both shorter in
the experimental group.
Postoperative complications
The postoperative complications, and their rates, are
summarized in Table 4. In the experimental group, gastro-
intestinal complications were most common, followed by
pulmonary complications or sepsis, with cardiovascular or
neurological complications being least common. In the
control group, gastrointestinal problems were still most
common, followed by nephrological and cardiovascular
complications, which were at similar rates, and then pul-
monary complications. Neurological complications and
sepsis were least common in this group. Although there
were no anastomotic leaks in the experimental group, one
patient developed an enterocutaneous fistula; by contrast,
8% of the control group developed anastomotic leakage.
There were no treatment-related deaths in either group.
Discussion
We investigated the feasibility and safety of neoadjuvant
chemotherapy before CRS and HIPEC. Our results show
that neoadjuvant chemotherapy did not influence either
the morbidity or the mortality rate. However, half of the
patients did need to stop neoadjuvant chemotherapy
early due to disease progression or complications. In a
study by Liu et al., it was reported that only 10.7% of
patients needed to stop neoadjuvant therapy [26]. This
difference may have arisen because the mean number of
completed cycles in their study was 2.7, compared with
4.2 in ours. In a study in which FOLFOX (folinic acid,
fluorouracil, and oxaliplatin) was used preoperatively,
the researchers showed that only 14% had to terminate
chemotherapy early [27]. This difference might be
explained by the bigger sample size of the study and the
fact that the goal of neo-adjuvant treatment was to make
unresectable metastases resectable. If this was not
possible, patients did not undergo surgery. However,
patients in our study were required to be sufficiently
healthy to tolerate CRS and HIPEC, so those with exten-
sive complications were not included.
Three of our patients (21%) showed tumor progression
during systemic chemotherapy, which is consistent with
prior research experience. Indeed, studies of patients
suffering from liver metastases due to CRC have shown
that 11.2% (4/36) or 23% (3/13) had disease progression
while receiving neoadjuvant chemotherapy [27, 28]. It
can be argued that these patients may miss out on
potentially curative surgery if they are selected for neo-
adjuvant treatment. However, failure of neoadjuvant
treatment can be indicative of the fact that a tumor is ei-
ther not chemosensitive or that the patient is too weak
to undergo further treatment. As such, the additional
value of CRS and HIPEC is questionable in these patients,
and tumor progression during neoadjuvant treatment may
be a contraindication to further surgery.
The rate of postoperative complications tends to be
high after CRS and HIPEC, with reports giving rates ran-
ging from 23 to 66% [2, 5, 12–15]. The most frequent
complications are small bowel leakage, digestive fistulas,
and abdominal sepsis [7, 13, 29]. Earlier studies of
neoadjuvant chemotherapy in patients with colorectal
liver metastases showed that there was a slight increase
in postoperative infections and blood loss with the
approach [16, 30]. In our study, however, the incidence
of postoperative complications did not differ between
the experimental and control groups. Compared with








15 days (range 2–38) 15 days (range 4–63)
Median length of
surgery (min)
485 (339–617) 502.50 (122–992)
Median blood loss (mL) 750 (100–2500) 700 (100–7000)
Resected organs
Hemicolectomy 2/8 43/110
(Sub)total colectomy 0/8 10/110
Pelvic peritoneum 6/8 81/110
Splenectomy 3/8 31/110
Small bowel resection 4/8 26/110
Cholecystectomy 2/8 23/110
CRS cytoreductive surgery, HIPEC hyperthermic intraperitoneal chemotherapy
Table 4 Complications after CRS and HIPEC
Experimental group N = 8 Control group N = 88
Cardiovascular 1 (12.5%) 20 (18.1%)
Pulmonary 2 (25%) 12 (10.9%)
Gastrointestinal 3 (37.5%) 31 (28.2%)
Sepsis/SIRS 2 (25%) 9 (8.1%)
Mental 1 (12.5%) 12 (10.9%)
Wound 2 (25%) 7 (6.4%)
Anastomotic leakage 0 (0%) 8 (7.2%)
Neurological 1 (12.5%) 2 (1.8%)
Nephrological 0 (0%) 19 (17.3%)
CRS cytoreductive surgery, HPEC hyperthermic intraperitoneal chemotherapy
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the historic control group, there were more pulmonary
(25% vs 11.4%), sepsis (25% vs 8%), and neurological
(12.5% vs 1.8%) complications in the experimental group,
and there were fewer cardiovascular complications (12.5%
vs 27.3%) and no renal complications (0% vs 19.3%).
To the best of our knowledge, this study is the first
prospective study of the feasibility and safety of neoadju-
vant chemotherapy before CRS and HIPEC. However,
there are some important limitations to this research.
Notably, the registration of complications in the historic
control group was controlled by a different research
team, and as such, was beyond our control. Also, the
study design and aim meant that we included few patients
from only one center, limiting our ability to generalize the
results. Furthermore, this study did not take into account
an eventual role of tumor biology or the influence of
RAS/RAF mutations on the efficacy of neoadjuvant
chemotherapy. Earlier studies have shown that that the
reaction to targeted chemotherapy and overall survival
might be influenced by these mutations in patients with
peritoneal carcinomatosis from colorectal cancer. This
should be taken into account when focusing on the
efficacy of neoadjuvant chemotherapy in future trials
[31, 32]. Finally, the median age was higher in the experi-
mental group, but this may have had limited relevance
because we observed no differences in complication rates.
In the future, a prospective randomized controlled trial
could answer the question whether neoadjuvant chemo-
therapy prior to CRS and HIPEC is effective in preventing
hematogenous and lymphogenous metastases.
Conclusion
In conclusion, postoperative complication rates, periopera-
tive blood loss, and length of surgery are not increased by
giving neoadjuvant treatment before CRS and HIPEC.
Therefore, it can be considered feasible and safe to perform
further study on the effects of neoadjuvant chemotherapy
before CRS and HIPEC. In the future, we aim to investigate
the efficacy of neoadjuvant chemotherapy in a multicenter
trial, specifically assessing not only its effect on survival but
also whether responsiveness to it could serve as a selection
criterion for CRS and HIPEC.
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